Prenatal Vitamin D Supplementation and Child Respiratory Health: A Randomised Controlled Trial

PLoS ONE
Q1
Jun 2013
Citations:166
Influential Citations:21
Interventional (Human) Studies
92
S2 IconPDF Icon

Enhanced Details

Methods
Ethnically stratified, parallel-group randomized controlled trial at St Mary's Hospital London; 180 pregnant women at 27 weeks gestation; exclusion criteria included sarcoidosis, osteomalacia, renal dysfunction or tuberculosis; offspring assessed at age 3 by investigators blinded to allocation.
Intervention
No vitamin D; 800 IU ergocalciferol daily from 27 weeks gestation until delivery; single 200,000 IU cholecalciferol bolus given at 27 weeks gestation.
Results
No significant difference in wheeze by age 3 between supplemented and control groups (wheeze ever: 14/50 [28%] vs 26/108 [24%]; risk ratio 0.86; 95% CI 0.49–1.50; P = 0.69). No differences in atopy, eczema, lung function or exhaled nitric oxide. Cord blood 25(OH)D higher in supplemented offspring (control 17 nmol/L; daily 26 nmol/L; bolus 25 nmol/L; P<0.001 for both). Conclusion: Late-pregnancy vitamin D supplementation (800 IU/day ergocalciferol or 200,000 IU cholecalciferol bolus) did not reduce wheeze or allergic outcomes by age 3, despite modest increases in cord blood vitamin D. Higher-dose or earlier supplementation may be needed; results may not generalize to vitamin D–replete populations; ongoing trials are exploring earlier/higher-dose strategies.
Limitations
Small sample size with limited power; participants not blinded to treatment; supplementation started at 27 weeks; modest cord blood 25(OH)D increases; only two dosing regimens studied; no genotypic data; results may not generalize to vitamin D–replete populations.

Abstract

Background Observational studies suggest high prenatal vitamin D intake may be associated with reduced childhood wheezing. We examined the effect of prenatal vitamin D on childhood wheezing in an interventional study. Methods We randomised 180 pregna...